

August 3, 2020

National Stock Exchange of India Ltd. (Symbol: INDUSINDBK)

BSE Ltd. (Scrip Code: 532187)

India International Exchange (Scrip Code: 1100027)

Madam / Dear Sir,

Sub: Newspaper Advertisement regarding Notice of the Extraordinary General Meeting of the Shareholders of IndusInd Bank Ltd. ('the Bank')

Please be informed that the Bank has issued a Newspaper Advertisement giving Notice of the Extraordinary General Meeting of the Shareholders of the Bank to be held on Tuesday, August 25, 2020, under the applicable provisions of the Companies Act, 2013, read with relevant Rules made thereunder, and other applicable Laws and Regulations, as amended and in terms of the Circulars issued by the Ministry of Corporate Affairs, Government of India vide its General Circular No. 14/2020 dated April 08, 2020 and General Circular No. 17/2020 dated April 13, 2020 (the 'MCA Circulars').

A copy of the Newspaper Advertisement dated August 3, 2020, published in the 'Financial Express' and 'Loksatta' is enclosed for your information and record

A copy of this letter is being uploaded on the Bank's website at **www.indusind.com**.

We request you to kindly take this letter on record.

Thanking you,

Yours faithfully,
For IndusInd Bank Ltd.

Haresh Gajwani
Company Secretary

Encl: a/a

IndusInd Bank Limited, Building No. 7, Solitaire Corporate Park, Andheri-Ghatkopar Link Road, Chakala, Andheri E, Mumbai - 400 093, India. Tel: (0022) 66412200

Registered Office: 2401 Gen. Thimmayya Road, Pune 411 001, India
Tel.: (020) 2634 3201 Fax: (020) 2634 3241 Visit us at www.indusind.com
CIN: L65191PN1994PLC076333



INTERVIEW: CHINAPPA MB, chief financial officer, Biocon Biologics India

'We plan to raise \$300 million over six months'

Setting a milestone of \$1-billion revenue by FY22, Biocon Biologics India, a subsidiary of Biocon, plans to raise funds in the \$200-\$300 million range over the next six months to increase its R&D portfolio and manufacturing. The demand for biosimilars in most of the world (MoW) markets is rapidly increasing which augurs well for its revenue growth prospects in FY21. It has one of the largest biosimilars' portfolios which includes 28 biosimilar molecules across diabetes, oncology, immunology, etc. In an interaction, Chinappa MB, chief financial officer, Biocon Biologics, tells BV Mahalakshmi that the company plans to invest \$200 million per year in capex for FY21 and FY22 to support capex and R&D requirements. Edited excerpts:

high-quality manufacturing infrastructure, we are confident of achieving our aspiration of serving five million patients through our biosimilars portfolio and achieving a target revenue of \$1 billion in FY22. Five molecules from Biocon Biologics' portfolio have been taken from lab to market, of which three have been commercialised in developed markets like EU, Australia, US, Canada and Japan.

How do you plan to utilise the \$30 million raised via the PE deal with Tata Capital? Do you have plans to raise more funds?

We have raised \$105 million so far this calendar year through two primary equity infusions. Through the latest round of primary equity investment by Tata Capital Growth Fund, we are raising \$30 million for a 0.85% minority stake in the biosimilar business. Earlier this year in January, we had raised \$75 million as primary equity infusion by True North Fund for a 2.44% stake in the business. The latest round of equity infusion is at a pre-money equity valuation of \$3.5 billion, representing a 22% increase in valuation compared to the last round and 44% increase on an annualised basis. As indicated last year, our total



fundraising plans are in the range of \$200-\$300 million. We expect to complete the balance fundraising over the next six months.

There are reports that Biocon is planning to list Biocon Biologics in the next two-three years. Can you provide more clarity on the IPO timeline?

We intend to list Biocon Biologics on the Indian capital markets in the next two to three years. However, it would be early to comment on specific IPO timelines as it is dependent on business performance and market conditions. As and when we are ready to approach the capital markets for an IPO, we will keep our shareholders informed on the timing and the potential size of the IPO offering.

How much is the capex lined up and how is it being funded?

Biocon Biologics has plans to invest \$200 million per year in capex for FY21 and FY22. This unlocking of value through PE funding will enable us to fund capex investments for further strengthening our business. Additionally, as the biosimilars business scales up and generates good margins that will also generate operating cash to fund our investment objectives.

Having the largest portfolio of biosimilars, what's the outlook for FY21?

In Q1FY21, our biosimilars business revenue rose 19% y-o-y to ₹692 crore. Sequentially, revenues rose 60% exhibiting a strong recovery from Q4FY20. We are very confident that the biosimilars business will demonstrate strong growth in FY21 on the back of significant contribution from Semelea, a biosimilar Insulin Glargine. The imminent launch of Semelea in the US by our partner, Mylan, will allow us to tap into a \$2.2-billion Glargine market opportunity. We also expect a full year of revenue from sales of Ogivri (biosimilar Trastuzumab) in the US to contribute to the annual performance. Sales of Fulphila

(biosimilar Pegfilgrastim) are also expected to improve, backed by recently expanded drug substance capacity. Mylan had launched Fulphila in the US in 2018 and recently launched the product in other developed markets, such as a few countries in Europe. We also expect Mylan to commercialise biosimilar Etanercept in Europe in the second half of this calendar year. For Etanercept, Biocon Biologics has shared economics.

Having provided over two billion doses of human insulin worldwide, your views on digital therapeutic solutions to improve patient outcomes and reduce costs to healthcare systems?

Earlier this month, we announced a global collaboration with Voluntas, a leader in digital therapeutics, to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. This makes Biocon Biologics one of the first insulin companies to offer a USFDA-cleared and CE-marked, highly validated digital therapeutic product, Insulia, to Type-2 diabetes patients, across several markets in the world.

UP minister succumbs to Covid

PRESS TRUST OF INDIA
Lucknow, August 2



Kamal Rani Varun

UTTAR PRADESH MINISTER Kamal Rani Varun, the only woman cabinet minister in the state, died of Covid-19 at a hospital here on Sunday. She was 62.

The technical education minister, who tested positive for Covid-19 on July 18 and is the first minister in the state to succumb to the disease, breathed her last at the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPIMS). She had comorbidities, including diabetes, hypertension and hyperthyroidism, a senior doctor at the hospital said.

Kamal Rani, who survived by her daughter, was cremated at the Bhairo Ghat crematorium here in accordance with Covid-19 protocols.

"A guard of honour was given as soon as her body reached Bhairo Ghat crematorium," district magistrate Brahmedo Ram Tiwari said.

The ambulance carrying her body wrapped in plastic reached the crematorium at 2 pm where family members, BJP colleagues and senior police and administration officials waited to pay their respects from a distance.

Kamal Rani, who was the MLA from Ghatampur in Kan-

Rani died around 9.30 am. "She was an experienced and capable leader. She discharged her responsibilities with competence. She was a dedicated public representative, who was always working for the welfare of deprived and oppressed sections of the society," Adityanath said in his message.

SGPIMS director Dr RK Dhiman said in a statement that the minister, who was put on a mechanical ventilator on Saturday, had been suffering from fever, cough and breathlessness.

"She also had comorbidities in the form of diabetes mellitus, hypertension, and hypothyroidism. She had bilateral pneumonia at admission and was shifted to ICU on the day of admission itself because of high oxygen requirement," he said.

Detailing the treatment given, he said she later required non-invasive ventilation with high oxygen requirements.

"On evaluation she had all the features of severe disease and she was given Inj. Remdesivir followed by Tocilizumab following which she had transient improvement in her clinical status for few days but again her condition started deteriorating with progressively increasing NIV and oxygen requirements," the statement said.

FPIs net buyers in July, invest ₹3,301 cr amid vaccine hopes

PRESS TRUST OF INDIA
New Delhi, August 2

FOREIGN PORTFOLIO INVESTORS (FPI) remained net buyers for the second consecutive month in July by pumping in ₹3,301 crore in Indian markets amid hopes of a Covid-19 vaccine.

According to the depositories data, a net sum of ₹7,563 crore was invested in equities while ₹4,262 crore were with-

drawn by FPIs between July 1-31.

The net investment during the month stood at ₹3,301 crore. In the previous month, FPIs put in a net ₹24,053 crore in Indian markets.

Some factors that led to investment in July include surge in markets which provided FPIs good profit booking opportunity and improvement in sentiment on the back of rising hopes of a coronavirus vaccine, said

Himanshu Srivastava, associate director — manager research, Morningstar India.

Noting that the investment in July was lower than that in June, Srivastava said FPIs adopted a "cautious stance" while investing in India as Covid-19 cases continued to surge even as many states implemented fresh lockdown measure thus fanning concerns that growth in the domestic economy could be

delayed further.

In the last week of July, FPI flows in emerging markets have been mixed with South Korea and India receiving positive

flows whereas most of other markets witnessing outflows, said Rusnik Oza, executive vice-president, head of fundamental research at Kotak Securities.

IndusInd Bank Limited

CIN: L65191PN1994PLC076333
Registered Office: 2401, Gen. Thimmayya Road (Cantonment), Pune - 411 001; Tel.: (020) 2623 4000
Secretarial & Investor Services Cell: 731, Solitaire Corporate Park, 167, Guru Hargovindji Marg, Andheri (East), Mumbai - 400 093; Tel.: (022) 6641 2487 / 2359
E-mail ID: investor@indusind.com; Website: www.indusind.com

NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF INDUSIND BANK LIMITED

NOTICE is hereby given that the Extraordinary General Meeting ('EGM') of the Members of IndusInd Bank Limited ('the Bank') is scheduled for **Tuesday, August 25, 2020 at 11.00 a.m. (IST)** through Video Conference (VC) to transact the business as set out in the 'Notice of EGM', in compliance with the provisions of the General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020 and 22/2020 dated June 15, 2020 issued by Ministry of Corporate Affairs and SEBI vide its Circular No. SEBI/HO/CFD/ CMD/1/CIR/P/2020/79 dated May 12, 2020 (collectively referred to as 'Applicable Circulars').

The Bank has, on August 2, 2020 completed the dispatch of the Notice of EGM to the Members through electronic mode, whose e-mail IDs were registered with the Bank/Link Intime India Private Limited, Registrar & Share Transfer Agent of the Bank ('RTA') Depository Participants.

Members may note that the Notice of the EGM is available on the Bank's website at www.indusind.com and on the websites of the Stock Exchanges, i.e., BSE Limited at www.bseindia.com and The National Stock Exchange of India Limited at www.nseindia.com and on National Securities Depositories Limited's (NSDL) website at www.evoting.nsdl.com.

Pursuant to Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), the Bank is pleased to provide its Members holding shares either in physical or in dematerialised form, the facility to cast their votes electronically on the business as set forth in the Notice of the EGM, by electronic means via Remote e-Voting platform and at the EGM through the e-Voting platform made available by National Securities Depository Limited ('NSDL'). The detailed procedure for e-voting is mentioned in the Notice of the EGM.

Members are informed that:

- **The cut-off date for determining eligibility to vote (through Remote e-Voting or using e-Voting System at the EGM) is Tuesday, August 18, 2020.**
- **Remote e-Voting shall commence at 9.00 a.m. (IST) on Saturday, August 22, 2020 and shall end at 5.00 p.m. (IST) on Monday, August 24, 2020.**

During this period, Members may cast their vote electronically. The Members will not be able to cast their vote electronically beyond the date and time mentioned above and the Remote e-Voting shall be disabled for voting by NSDL thereafter.

- Members attending the EGM and those who have not cast their votes through Remote e-Voting may cast the same at the EGM through Electronic Voting System.
- Members who have already cast their vote through Remote e-Voting may participate in the EGM but shall not be entitled to vote again or change their votes at the EGM.

- Only those persons whose names are recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the cut-off date, i.e., Tuesday, August 18, 2020, shall be entitled to avail the facility of e-Voting.

A person who is not a Member as on the cut-off date should treat this Notice as for information purpose only.

- Any person who acquires shares and becomes a Member of the Bank after dispatch of the Notice and holds shares of the Bank as on the cut-off date, i.e., Tuesday, August 18, 2020, may obtain the Login ID and Password for e-Voting by sending an e-mail request to evoting@nsdl.co.in mentioning his / her Folio No. / DP ID and Client ID. Members who are already registered with NSDL for Remote e-Voting can use their existing User ID and Password for casting their votes.

If a Member has not yet registered his / her e-mail address with Bank / RTA / Depository Participants, please register / update your details as stated below:

In Physical form	Send a request to the RTA at mt.helpdesk@linkintime.co.in and provide your Folio No., Name of the Shareholder, scanned copy of the Share Certificate (front and back), self-attested scanned copy of PAN Card as well as Aadhaar Card. The Bank has also enabled a process with the RTA, for the limited purpose by providing the basic credentials which may be asked for verification during the process. The link for updating the details is available at https://linkintime.co.in/emailreg/email_register.html . Shareholders can also update their Bank details, PAN, Aadhaar number, etc. and upload a copy of the same on the above-mentioned link.
In Demat form	Contact your Depository Participant and register your e-mail address and Mobile Number for your Demat Account, as per the process advised.

In case of any queries, you may refer to the 'Frequently Asked Questions' (FAQs) for Shareholders and the e-Voting User Manual for Shareholders available at the download section of www.evoting.nsdl.com / call on Toll-free Number 1800-222-990 / send a request at evoting@nsdl.co.in. Alternatively, you may contact Mrs. Pallavi Mhatre, Assistant Manager, NSDL on Tel. No. 91 22 2499 4545 or write to her at Trade World, 'A' Wing, 4th Floor, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013.

The Board of Directors of the Bank has appointed Mr. S. N. Bhandari (C.P. No. 366), or failing him Ms. Manisha Maheshwari (C.P. No. 11031), Practising Company Secretaries, from M/s Bhandari & Associates, Company Secretaries, as the Scrutinizer to scrutinize the e-Voting process in a fair and transparent manner.

The results of the electronic voting shall be declared to the Stock Exchanges, within 48 (forty-eight) hours of the conclusion of the EGM pursuant to Regulation 44 of the SEBI LODR.

For IndusInd Bank Limited
sd/-
Haresh K. Gajwani
Company Secretary
Membership No. A18225

Place: Mumbai
Date: August 2, 2020

IDFC MUTUAL FUND

NOTICE is hereby given to all investor(s)/Unit Holder(s) of IDFC Mutual Fund ('the Fund') that in accordance with Regulation 54 of Securities and Exchange Board of India (Mutual Funds) Regulations, 1996 read with SEBI circular no. SEBI/HO/IMD/DF2/CIR/P/2018/92 dated June 05, 2018 the Annual Report and the Abridged Annual Report of the schemes of the Fund for the financial year ended March 31, 2020, has been hosted on the website of the Fund viz. www.idfcmf.com and on the website of AMFI viz. www.amfiindia.com.

Investors may view/download the electronic copy of the reports from the website of the fund. Investors can also request for a physical copy of the Annual Report or the Abridged Annual Report through any of the following means:

1. Phone - Give a call at our Contact Centre at 1-800-266 6688 or 1-800-300 666 88.
2. E-mail - Send an e-mail to investormf@idfc.com.
3. Letter - Submit a letter at any of the CAMS Investor Service Centres, list available at www.idfcmf.com.

Date: July 31, 2020
Place: Mumbai

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS. READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.

MAGNA ELECTRO CASTINGS LIMITED
(CIN:L31103TZ1990PLC002836)
Regd. Office: 43, Balasundaram Road, Coimbatore - 641018.
Phone: 0422 - 2240109 | Email: info@magnacast.com | Website: www.magnacast.com

NOTICE
(For the attention of Equity Shareholders of the Company)
Sub.: Transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) Authority

This Notice is published pursuant to the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 notified by the Ministry of Corporate Affairs effective September 7, 2016 and amendments made thereto (referred to as 'the Rules').

The Rules, amongst other matters, contain provisions for transfer of all shares in respect of which dividend has remained unpaid or unclaimed by the shareholders for seven consecutive years or more in the name of Investor Education and Protection Fund (IEPF) Authority.

The Company has, vide registered post letter dated 28.07.2020 communicated individually to the concerned shareholders whose shares are liable to be transferred during the financial year 2020-2021 to IEPF Authority under the said Rules.

The Company has uploaded details of such shareholders whose shares are due for transfer to IEPF Authority on its website at www.magnacast.com. Shareholders are requested to verify.

Shareholders may note that both the unclaimed dividend and the shares transferred to IEPF Authority including all benefits accruing on such shares, if any, can be claimed back from IEPF Authority after following the procedure prescribed under the Rules.

The concerned shareholders, holding shares in physical form and whose shares are liable to be transferred to IEPF Authority, may note that the Company would be issuing duplicate share certificate(s) in lieu of the original share certificate(s) held by them for the purpose of dematerialization and transfer of shares to IEPF Authority as per Rules and upon such issue, the original share certificate(s) which stand registered in their name will stand automatically cancelled and be deemed non-negotiable. The shareholders may further note that the details uploaded by the Company on its website should be regarded and shall be deemed adequate notice in respect of issue of the duplicate share certificate(s) by the Company for the purpose of transfer of shares to IEPF Authority pursuant to the Rules.

In case the Company does not receive any communication from the concerned shareholders within three months from the date of this notice, the Company shall transfer the shares to IEPF Authority as per procedure stipulated in the Rules.

In case the shareholders have any queries on the subject matter, they may contact the Company's Registrar and Transfer Agents at S.K.D.C. Consultants Ltd., Kanapally Towers, 3rd Floor, Saihy Road, Ganapathy, and Coimbatore 641006. Phone: +91 422 4959955 / 2539835-836 | Fax: +91 422 2539837 | Email: info@skdc-consultants.com

For Magna Electro Castings Limited
sd/-
N Krishna Samraj
Managing Director

Place: Coimbatore
Date: 03.08.2020

Edelweiss | MUTUAL FUND
Ideas create, values protect

801, 802 & 803, 8th Floor, Windsor, Off C.S.T. Road, Kalina, Santacruz (E), Mumbai 400 098

NOTICE CUM ADDENDUM TO THE SCHEME INFORMATION DOCUMENT (SID), KEY INFORMATION MEMORANDUM (KIM) AND STATEMENT OF ADDITIONAL INFORMATION (SAI) OF THE SCHEMES OF EDELWEISS MUTUAL FUND

CHANGE IN ADDRESS OF OFFICIAL POINT OF ACCEPTANCE OF TRANSACTIONS:

Investors/Unit holders are advised to take note of the following change in address of Investor Service Centre of KFin Technologies Private Limited (Registrar and Transfer Agent to the Schemes of Edelweiss Mutual Fund) which will be the official point of acceptance of transactions for all the Schemes of Edelweiss Mutual Fund ("the Fund"):

Branch	Old Address	New Address	Effective Date
Amritsar	KFin Technologies Pvt. Ltd., 72-A, Taylor's Road, Opp. Aga Heritage Club, Amritsar - 143001 Phone Number - 0183-5053802	KFin Technologies Private Limited, SCO 5, 2 nd Floor, District Shopping Complex, Ranjit Avenue, City- Amritsar, Punjab - 143001 Phone Number - 0183-5158158	August 3, 2020
Dharwad	KFin Technologies Pvt. Ltd., 307/9-A, 1 st Floor Nagarkar Colony, Elite Business Center, Nagarkar Colony, P. B. Road, Dharwad - 580001 Phone Number - 0836-2744207	KFin Technologies Pvt. Ltd, Adinath Complex, Beside Kamal Automobiles, Bhoovi Galli, Opp. Old Laxmi Talkies, P. B. Road, Dharwad - 580001 Phone Number - 0836-2440200	
Panjim	KFin Technologies Pvt. Ltd., Flat No. 1-A H. No. 13/70, Timotio Bldg., Heliador Salgado Road Next to Navhind Bhavan (Market Area), Panjim - 403001 Phone Number - 0832-2426874	KFin Technologies Pvt. Ltd, H. No: T-9, T-10, Affran Plaza, 3 rd Floor, Near Don Bosco High School, Panjim Goa - 403001 Phone Number - 0832-2426874	
Patiala	KFin Technologies Pvt. Ltd., SCO 27D, Chotti Baradari, Near Car Bazaar, Patiala - 147001 Phone Number - 0175-5004349	KFin Technologies Pvt. Ltd., B-17/423 Opp. Modi College, Lower Mall Patiala - 147001 Phone Number - 0175-5004349	

Accordingly, the Scheme Information Document (SID), Key Information Memorandum (KIM) and Statement of Additional Information (SAI) of the Schemes of Edelweiss Mutual Funds stands amended suitable to reflect the change as stated above.

This addendum shall form an integral part of the SID/KIM/SAI of the Schemes of the Fund, as amended from time to time.

For Edelweiss Asset Management Limited
(Investment Manager to Edelweiss Mutual Fund)
sd/-
Radhika Gupta
Managing Director & CEO

Place: Mumbai
Date: August 1, 2020

For more information please contact:
Edelweiss Asset Management Limited (Investment Manager to Edelweiss Mutual Fund)
CIN: U65991MH2007PLC173409
Registered Office: Edelweiss House, Off C.S.T. Road, Kalina, Mumbai - 400098
Corporate Office: 801, 802 & 803, 8th Floor, Windsor, Off C.S.T. Road, Kalina, Santacruz (E), Mumbai 400 098
Tel No:- 022 4093 3400 Toll Free No. 1800 425 0090 (MTNL/BSNL), Non Toll Free No. 91 40 23001181,
Fax: 022 4093 3401 / 4093 3402 / 4093 3403, Website: www.edelweissmf.com

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.

